GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » PE Ratio

Repligen (Repligen) PE Ratio

: 218.25 (As of Today)
View and export this data going back to 1986. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-19), Repligen's share price is $157.14. Repligen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.72. Therefore, Repligen's PE Ratio for today is 218.25.


The historical rank and industry rank for Repligen's PE Ratio or its related term are showing as below:

RGEN' s PE Ratio Range Over the Past 10 Years
Min: 14.72   Med: 97.06   Max: 312.18
Current: 218.25


During the past 13 years, the highest PE Ratio of Repligen was 312.18. The lowest was 14.72. And the median was 97.06.


RGEN's PE Ratio is ranked worse than
96.08% of 408 companies
in the Medical Devices & Instruments industry
Industry Median: 26.735 vs RGEN: 218.25

Repligen's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.46. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.72.

As of today (2024-04-19), Repligen's share price is $157.14. Repligen's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $1.73. Therefore, Repligen's PE Ratio without NRI for today is 90.83.

During the past 13 years, Repligen's highest PE Ratio without NRI was 154.29. The lowest was 14.70. And the median was 71.02.

Repligen's EPS without NRI for the three months ended in Dec. 2023 was $0.33. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $1.73.

During the past 12 months, Repligen's average EPS without NRI Growth Rate was -46.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was 2.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 26.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 26.10% per year.

During the past 13 years, Repligen's highest 3-Year average EPS without NRI Growth Rate was 78.10% per year. The lowest was -130.10% per year. And the median was 13.10% per year.

Repligen's EPS (Basic) for the three months ended in Dec. 2023 was $-0.46. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.75.


Repligen PE Ratio Historical Data

The historical data trend for Repligen's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 210.23 172.64 118.23 52.26 242.97

Repligen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.26 57.07 58.45 78.33 242.97

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Repligen's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen PE Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's PE Ratio distribution charts can be found below:

* The bar in red indicates where Repligen's PE Ratio falls into.



Repligen PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Repligen's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=157.14/0.720
=218.25

Repligen's Share Price of today is $157.14.
Repligen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.72.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Repligen  (NAS:RGEN) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Repligen PE Ratio Related Terms

Thank you for viewing the detailed overview of Repligen's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen (Repligen) Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Executives
Christine Gebski officer: See Remarks C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot officer: President and CCO C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland officer: CFO 10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres officer: CFO REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt director, officer: Chief Executive Officer 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel officer: Senior VP, R&D 41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund officer: SVP, Global Operations & IT C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov director C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr director
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox director C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre director C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453

Repligen (Repligen) Headlines

From GuruFocus

Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors

By GuruFocusNews GuruFocusNews 06-25-2022

Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors

By GuruFocusNews GuruFocusNews 07-05-2022

Repligen to Report Second Quarter 2022 Financial Results

By PurpleRose PurpleRose 07-19-2022

Repligen to Report Fourth Quarter and Full Year 2022 Financial Results

By Stock market mentor Stock market mentor 02-08-2023

Repligen To Host Investor Day 2022

By PurpleRose PurpleRose 08-24-2022

Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors

By GuruFocusNews GuruFocusNews 06-15-2022